학술논문
Treatment of Nonproliferative Diabetic Retinopathy with a Peptide Fraction from Bovine Factor VIII: A Multicentre Controlled Trial
Document Type
Original Paper
Author
Source
Drug Investigation. February 1992 4(1):1-6
Subject
Language
English
ISSN
0114-2402
1179-1918
1179-1918
Abstract
Summary:28 patients with diabetic retinopathy randomly received oral treatment with a bovine factor VIII peptide fraction (Vueffe®) 0.5mg twice daily or calcium-dobesilate (Doxium®) 500mg twice daily for 4 months. Changes in the activity of plasma factor VIII fractions [von Willebrand factor (vWf); factor VIII-related antigen (FVIII:Ag); and factor VIII procoagulant activity (FVIII:C)] were determined during treatment, and compared at baseline with a control group of 10 diabetic patients without retinopathy. Bovine factor VIII peptide fraction reduced the high levels of vWf and FVII:Ag to values found in control patients without retinopathy, while no effect on FVIII:C was detected. Bovine factor VIII peptide fraction produced a statistically significantly greater reduction in vWf and FVIII:Ag than calcium-dobesilate: the percentage reduction of vWf was 33 vs 11 (p < 0.01), that of FVIII:Ag was 25 vs 7 (p < 0.01). In addition, the retinopathy improvement rate was 47% for bovine factor VIII peptide fraction and 8% for calcium-dobesilate (p = 0.037). It is concluded that bovine factor VIII peptide fraction improves diabetic retinopathy by lessening endothelial damage to retinal microvessels by reducing plasma vWf and FVIII:Ag activity.